SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ahlqvist Rastad Jane)
 

Sökning: WFRF:(Ahlqvist Rastad Jane) > Antiretroviral trea...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004903naa a2200649 4500
001oai:gup.ub.gu.se/83665
003SwePub
008240528s2003 | |||||||||||000 ||eng|
009oai:DiVA.org:uu-65602
009oai:prod.swepub.kib.ki.se:1952762
0247 a https://gup.ub.gu.se/publication/836652 URI
0247 a https://doi.org/10.1080/003655403100063952 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-656022 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:19527622 URI
040 a (SwePub)gud (SwePub)uud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
1001 a Sandström, Ericu Karolinska Institutet4 aut
2451 0a Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations
264 c 2009-07-08
264 1b Informa UK Limited,c 2003
520 a The Swedish guidelines (SwG) for treatment of human immunodeficiency virus (HIV) infection have several important roles. A major task involves the promotion of a uniformly high standard of care in all HIV treatment clinics in Sweden and the identification of strengths, weaknesses and relevance of recent research findings. CD4+ T-cell counts < 200 cells/microl are clear indications for the initiation of treatment, whereas high viral loads serve as an indication for increased vigilance rather than a criterion for therapy. It is recommended that the first regimen consists of 2 nucleoside reverse transcriptase inhibitors in combination with 1 protease inhibitor or 1 non-nucleoside reverse transcriptase inhibitor. The definition of treatment failure is rigorous. Treatment change should be considered if the viral load has not fallen by at least 1.5 log in 4 weeks or is undetectable within 3-4 months. Resistance testing is endorsed at primary infection, in the event of treatment failure and in pregnant women. Interaction with experts in HIV resistance testing is emphasized. Therapeutic drug monitoring is advocated. Patients with treatment failure should be handled individually and the decision on therapeutic strategy should be based on treatment history, resistance testing and other clinical facts. The SwG do not give recommendations for some important issues such as prolonged drug holidays and preferences in initial treatment regimens. More scientific data are likely to be available soon and the SwG will be refined accordingly. The present guidelines are translated from Swedish; they are published on the Medical Products Agency (MPA) and Swedish Reference Group for Antiviral Therapy (RAV) websites (www.mpa.se and www.rav.nu.se), including 7 separate papers based on a thorough literature search. A complete reference list is available on request from the MPA.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Mikrobiologi inom det medicinska området0 (SwePub)301092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Microbiology in the medical area0 (SwePub)301092 hsv//eng
653 a Anti-HIV Agents/*administration & dosage
653 a Antiretroviral Therapy
653 a Highly Active/*standards
653 a Female
653 a HIV Infections/diagnosis/*drug therapy
653 a *Health Planning Guidelines
653 a Humans
653 a Male
653 a Practice Guidelines as Topic
653 a Prognosis
653 a Sensitivity and Specificity
653 a Survival Analysis
653 a Sweden
653 a Treatment Outcome
653 a MEDICINE
7001 a Uhnoo, Ingridu Uppsala universitet,Institutionen för medicinska vetenskaper,Infektion, Göran Friman4 aut
7001 a Ahlqvist-Rastad, Jane4 aut
7001 a Bratt, Göranu Karolinska Institutet4 aut
7001 a Berglund, Torstenu Karolinska Institutet4 aut
7001 a Gisslén, Magnus,d 1962u Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för infektionssjukdomar,Institute of Internal Medicine, Dept of Infectious Diseases4 aut0 (Swepub:gu)xgissm
7001 a Lindbäck, Stefan4 aut
7001 a Morfeldt, Linda4 aut
7001 a Ståhle, Lars4 aut
7001 a Sönnerborg, Andersu Karolinska Institutet4 aut
7102 a Karolinska Institutetb Institutionen för medicinska vetenskaper4 org
7730 t Scand J Infect Disd : Informa UK Limitedg 35:3, s. 155-67q 35:3<155-67
7730 t Scandinavian Journal of Infectious Diseasesd : Informa UK Limitedg 35:3, s. 155-67q 35:3<155-67x 0036-5548x 1651-1980
8564 8u https://gup.ub.gu.se/publication/83665
8564 8u https://doi.org/10.1080/00365540310006395
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-65602
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1952762

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy